Management of inflammatory bowel disease

Purva Grover, Deepak Kamat

Research output: Contribution to journalReview article

1 Scopus citations

Abstract

In considering the optimal medical therapy of IBD, it is important to individualize treatment according to the particular needs of the patients. Improving and maintaining the patient's quality of life is the most important goal. For ulcerative colitis, it is important to remember that topical therapy can be useful in distal disease and that the higher the dose of 5-ASA, the better the response. For Crohn's disease, activity should be treated according to severity. Budesonide is a promising drug for mild-to-moderate ileitis and right-sided colitis, and infliximab is an effective therapy for moderate-to-severe inflammatory and fistulizing Crohn's disease. For both ulcerative colitis and Crohn's disease, corticosteroids are effective in inducing remission but not maintaining it. Newer advances in medical therapy and diligence by physicians and patients alike should make IBD a more tolerable disease.

Original languageEnglish (US)
Pages (from-to)359-364
Number of pages6
JournalClinical Pediatrics
Volume46
Issue number4
DOIs
StatePublished - May 1 2007
Externally publishedYes

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Management of inflammatory bowel disease'. Together they form a unique fingerprint.

  • Cite this